Old Web
English
Sign In
Acemap
>
authorDetail
>
Gabriel Alejandro Bien-Willner
Gabriel Alejandro Bien-Willner
Medicine
Cancer research
Adenocarcinoma
ALK Rearrangement
Gefitinib
4
Papers
2
Citations
0
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (4)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Analysis of use of a molecular reporting and treatment decision support tool in more than 1300 cancer cases.
2018
Journal of Clinical Oncology
Gabriel Alejandro Bien-Willner
Carolin Hülsewig
David B. Jackson
Sajo Kaduthanam
Stephan Brock
Martin Stein
Stephan Hettich
Michael Weber
Matthias Loehr
Show All
Source
Cite
Save
Citations (0)
Response to crizotinib and gefitinib in a lung adenocarcinoma patient harboring a concurrent EGFR exon 21 mutation and an ALK rearrangement.
2016
Journal of Clinical Oncology
Gabriel Alejandro Bien-Willner
Dong Yang
Christopher M. McCanless
Elizabeth Mambo
Show All
Source
Cite
Save
Citations (0)
Coexistence of driver aberrations in NSCLC patients including ALK/RET/ROS1 rearrangements.
2016
Journal of Clinical Oncology
Gabriel Alejandro Bien-Willner
Dong Yang
Dianren Xia
Jixin Wang
Sandra Indiviglio
Jamie Renard
George Miles
Elizabeth Mambo
Show All
Source
Cite
Save
Citations (1)
Relationships of clinical response to relevant molecular signal during Phase I testing of Aurora Kinase A inhibitor: Retrospective assessment
2015
Integrative molecular medicine
John Nemunaitis
Christopher Blend
Gabriel Alejandro Bien-Willner
Meghan Degele
Alyssa Roth
Stacey Hayes
Leah Plato
Andrew Guo
James Nemunaitis
David B. Jackson
Neil Senzer
Show All
Source
Cite
Save
Citations (1)
1